Compare · Head-to-head
BPC-157 vs Thymosin Beta-4.
Evidence, risk, regulatory flags, cost, and vendor coverage compared side by side. We don’t sell peptides — we help you choose between them.
Which should you research first?
Start with Thymosin Beta-4, then use the table to confirm fit.
Thymosin Beta-4 is the cleaner first read based on the current evidence, risk, and regulatory data stored for this pair. The right answer can still change if your goal, sport testing status, vendor constraints, or monitoring tolerance makes the other option a better fit.
Comparison next step
Personalize this head-to-head.
Take the quiz before converting a comparison into a compound, vendor, or protocol decision.
01· Subject
BPC-157
Preclinical cytoprotective peptide studied for tissue repair and GI protection in animal models.
01 · At a glance
| Decision factor | BPC-157 | Thymosin Beta-4 |
|---|---|---|
| Primary fit | tissue repair & recovery research where you want a clear starting point | tissue repair & recovery and immune support comparisons |
| Evidence | Tier C | Tier B-C |
| Risk | med-high | med-high |
| Experience level | intermediate | intermediate |
| Budget tier | mid | mid |
| Administration route | subcutaneous, oral | topical, subcutaneous |
02 · Use case & timing
| Decision factor | BPC-157 | Thymosin Beta-4 |
|---|---|---|
| Goal fit | Tissue Repair & Recovery | Tissue Repair & Recovery, Immune Support |
| What users compare it for | Preclinical: angiogenesis markers, tissue repair signals, GI mucosal protection in rodent models. | Ophthalmic: improved corneal epithelial healing. Systemic: wound healing signals in preclinical models. |
| Onset timeline | Animal models: endpoints assessed over days to weeks (2-4 weeks in injury models). | Corneal healing studies: days to weeks; systemic repair claims are less well-timed. |
| Main tradeoff | Evidence and product availability can still be uneven, so documentation matters more than hype. | Evidence and product availability can still be uneven, so documentation matters more than hype. |
03 · Safety & restrictions
| Decision factor | BPC-157 | Thymosin Beta-4 |
|---|---|---|
| Adverse effects | Insufficient human data; immunogenicity risk flagged by FDA; impurity characterization concerns. | Human ophthalmic safety reported as acceptable in trials; systemic safety requires caution. |
| Contraindications | No established human contraindications (insufficient data). | Limited formal contraindication data. |
| Interaction notes | No robust human interaction map; avoid confident stacking claims. | Limited formal interaction studies; treat as unknown outside studied settings. |
| Regulatory status | Not approved | Investigational |
| FDA flag | FDA compounding caution | FDA compounding caution |
| WADA status | WADA S0 | WADA S2 |
04 · Age & monitoring
| Decision factor | BPC-157 | Thymosin Beta-4 |
|---|---|---|
| Supported age ranges | 25-34, 35-44, 45-54, 55-64 | No age guidance yet |
| Life-stage note | Commonly researched by active adults for recovery, but still lacks validated human age-specific evidence. | Not yet documented |
| Monitoring burden | Not specified | Not specified |
| Follow-up cadence | Not yet documented | Not yet documented |
05 · Cost & sourcing
| Decision factor | BPC-157 | Thymosin Beta-4 |
|---|---|---|
| Typical cycle cost | $118.99 | $192.00 |
| Estimated monthly cost | $79.32 | $96.00 |
| Cost confidence | High confidence | High confidence |
06 · Before you buy
| Decision factor | BPC-157 | Thymosin Beta-4 |
|---|---|---|
| Tracked vendor listings | 3 listings | 1 listing |
| Sourcing note | Product format varies by listing, so double-check route, concentration, and presentation. | Product format varies by listing, so double-check route, concentration, and presentation. |
| Stack-friendly? | Usually stack-friendly | Usually stack-friendly |
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Still deciding
Get a plan tailored to you.
The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.